RECRUITING

Sit Less, Interact and Move More (SLIMM) 2 Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Official Title

Sit Less, Interact and Move More (SLIMM) 2 Study

Quick Facts

Study Start:2021-12-01
Study Completion:2027-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05173714

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:20 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
  2. * Able to perform resistance training
  3. * Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop
  1. * Type 1 Diabetes
  2. * History of gastroparesis or paralytic ileus
  3. * At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
  4. * Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
  5. * Previous bariatric surgery
  6. * Medical condition likely to limit survival to less than 1 year
  7. * Anticipated start of dialysis or kidney transplantation within 6 months
  8. * Any factors judged by the investigator or study team to likely limit adherence to interventions
  9. * Vulnerable populations- pregnant or incarcerated
  10. * Enrolled in interventional trials using drugs or devices
  11. * Not able to undergo informed consent
  12. * Recent hospitalizations or major interventional procedures done within the past 60 days
  13. * Known or suspected hypersensitivity to tegaderm
  14. * Use of any GLP-1 receptor agonist within 30 days prior to screening
  15. * Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
  16. * Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
  17. * Presence of metastatic cancer
  18. * Current use of mobility aid(s)
  19. * Living in the same household of a participant already enrolled in the study

Contacts and Locations

Study Contact

Amara Sarwal, M.D.
CONTACT
801-585-9815
Amara.Sarwal@hsc.utah.edu

Principal Investigator

Srinivasan Beddhu, M.D.
PRINCIPAL_INVESTIGATOR
University of Utah

Study Locations (Sites)

Stanford University
Stanford, California, 94305
United States
University of Utah
Salt Lake City, Utah, 84108
United States

Collaborators and Investigators

Sponsor: Srinvasan Beddhu

  • Srinivasan Beddhu, M.D., PRINCIPAL_INVESTIGATOR, University of Utah

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-12-01
Study Completion Date2027-03-31

Study Record Updates

Study Start Date2021-12-01
Study Completion Date2027-03-31

Terms related to this study

Additional Relevant MeSH Terms

  • Chronic Kidney Diseases
  • Obesity